Bone replacements, human tissue and prosthetics are being created by 3-D bioprinters. The science will soon be used to customize drugs.» Read More
It also sends a lofty message to cross-town rival Novartis and other drugmakers that Roche, the world's biggest cancer drug company, is determined to retain its leadership of the $100 billion- a-year oncology market, despite mounting competition. Roche said its decision to erect "Building 1," as the tower is prosaically called, is motivated by a dearth of space at...
Sept 17- Advaxis Inc said its experimental cancer vaccine was found more effective in improving survival rates of cervical cancer patients than standard therapy, validating the technology behind its pipeline of cancer treatments. About 38.5 percent of the patients in a mid-stage study, whose disease had progressed or returned after prior therapy, survived...
U.S. stocks closed more than 1 percent higher as investors eyed some of the final data reports leading into the Federal Reserve's key meeting.
U.S. stocks closed lower as investors weighed mostly negative stock performance overseas and eyed the Federal Reserve meeting later in the week.
U.S. stocks closed higher, off session highs as a bounce in oil and stocks failed to completely offset uncertainty ahead of the Fed meeting next week.
Sept 8- Tetraphase Pharmaceuticals Inc said its experimental bowel drug failed to meet the main goal in a late-stage study, sending its shares down 75 percent in extended trading. The company said on Tuesday that data from the study showed that the drug was not better than Johnson& Johnson's antibiotic, levofloxacin, to treat complicated urinary tract...
U.S. stocks closed more than 1 percent lower ahead of a long weekend as uncertainty about the timing of a rate hike and Chinese growth weighed.
Sept 2- The U.S. Food and Drug Administration approved Tesaro Inc's treatment for chemotherapy-induced nausea and vomiting in adults, the company said on Wednesday. The drug, known chemically as rolapitant, was approved in combination with other agents to prevent delayed nausea and vomiting associated with some forms of chemotherapy, Tesaro said.
U.S. stocks closed lower on the last day of trade for August as investors digested a volatile month amid uncertainty about China and the Fed.
The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006, when the first one was approved, through Dec. 31, 2013. Five cases were reported with AstraZeneca Plc's Onglyza, two with Boehringer Ingelheim's Tradjenta, and one with Takeda Pharmaceutical's Nesina.
U.S. stocks shot higher on Wednesday, rebounding from six consecutive days of declines that pushed the major averages into correction territory.
U.S. stocks closed lower, after a failed attempt to rally, as investor confidence waned amid continued concerns about China and global growth.
U.S. stocks closed near session lows as investors weighed continued uncertainty about the timing of a rate hike and concerns about global growth.
Stocks pared gains and closed mostly lower on Thursday.
Alex Arfaei of BMO Capital Markets upgraded Merck to "outperform" Thursday morning in a note sent to clients.
Some of the names on the move ahead of the open.
U.S. stocks closed off lows, recovering from sharp intraday declines as gains in energy offset earlier pressures from global growth concerns.
Pfizer Inc, which is lagging rivals in the lucrative field of cancer immunotherapies, has been the first to report early data of an "accelerator" treatment that targets a protein called 4-1 BB. Bristol-Myers Squibb Co is hot on Pfizer's heels with a handful of early-stage trials of its own 4-1 BB antibody. Holbrook Kohrt, a researcher from Stanford University...
Aug 6- Irish drugmaker Allergan Plc reported better-than-expected revenue for the first full quarter since the merger of Actavis and Allergan. Allergan, which changed its name from Actavis after the deal closed, said adding signature drugs like Botox and eye drops Restasis boosted branded products sales five-fold to $3.71 billion in the second quarter...
A vaccine being developed by Merck and NewLink was shown to be 100 percent effective, but does this mean they'll make big bucks?